ImmunityBio (IBRX) said Tuesday it completed submissions to the US Food and Drug Administration, including the supplemental biologics license application for ANKTIVA plus Bacillus Calmette-Guerin to treat BCG-unresponsive non-muscle invasive bladder cancer in papillary disease.
The company also submitted an expanded access protocol to the FDA to make ANKTIVA available for the treatment of lymphopenia, according to a statement.
ImmunityBio also reported preliminary net product revenue of about $16.5 million for Q1, up from $7.2 million in Q4.
Price: 2.91, Change: +0.02, Percent Change: +0.69
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。